Clinical Trials Browser

Pancreatic Neoplasms × sintilimab × 90 days × Clear all

NCT06050317 2026-05-01

Sintilimab Combined With Chemotherapy and Radiotherapy in Patients With Inoperable Pancreatic Cancer

Phase 2 Recruiting

Gastrointestinal

Pancreatic Neoplasms